On November 2, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma (Press release, Harpoon Therapeutics, NOV 2, 2023, View Source [SID1234636824]). The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the ASH (Free ASH Whitepaper) presentation are as follows:
Title: Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Publication Number: 1012
Presenter: Sumit Madan, M.D., Banner MD Anderson Cancer Center
Session Name: 653. Multiple Myeloma: Prospective Therapeutics Trials: Relapsed and Refractory Myeloma
Session Room: Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD
Date: Monday, December 11, 2023
Time: Viewing – 4:30 to 6:00 p.m. PT / 7:30 to 9:00 p.m. ET, Presentation – 5:15 p.m. PT / 8:15 p.m. ET
The presentation will also be available on Harpoon’s website following the session.
For more details about the ASH (Free ASH Whitepaper) Annual Meeting, please visit:
View Source